NetworkNewsBreaks Archive - Page 426 of 2173

WednesdayMay 08, 2024 2:13 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Dosing of Human Pilot Study No. 2, GLP-1-H24-2

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its second human pilot study, GLP-1-H24-2, is underway and the first dosing visit for all nine study participants has concluded. The three-arm, crossover study will compare three 7 mg semaglutide dose formulations: A positive control Rybelsus(R) swallowed tablet (already dosed); DehydraTECH-semaglutide swallowed capsules; and, for the first time ever, an in-mouth dissolvable DehydraTECH-semaglutide oral tablet. According to the announcement, the second DehydraTECH study arm will use a Rybelsus(R) composition processed with DehydraTECH that is compliant with the U.S. Food and Drug Administration’s Inactive Ingredient Database…

WednesdayMay 08, 2024 2:04 pm

NetworkNewsBreaks – SuperCom Ltd. (NASDAQ: SPCB) Schedules Release of Q1 2024 Financial Results, Conference Call

SuperCom (NASDAQ: SPCB), a global provider of secured solutions for the e-government, IoT and cybersecurity sectors, will hold a conference call at 10 a.m. Eastern Time on Wednesday, May 15, 2024, to discuss its financial results for the first quarter ended March 31, 2024. According to the announcement, financial results will be issued in a press release prior to the call. Interested parties should visit https://nnw.fm/f1qcL to register for the event and dial 888-506-0062 (U.S. toll-free), 1-809-423-853 (Israel toll-free) or 973-528-0011 (international) and state SuperCom as the access code to join the call. Attendees are asked to join via the…

WednesdayMay 08, 2024 1:56 pm

NetworkNewsBreaks – Advanced Gold Exploration Inc. (CSE: AUEX) (OTC: AUHIF) (FSE: 4TG) Notes Industry Interest in Copper, Provides Update on Its Buck Lake Project

Advanced Gold Exploration (CSE: AUEX) (OTC: AUHIF) (FSE: 4TG), a junior mining company bringing an entirely different approach to the mining industry, released a statement noting the interest in copper and the recent increases in the price of the metal. The company is interested in copper and its role in electric vehicle development as well as reducing greenhouse-gas emissions and is developing its own copper project, Buck Lake. The statement noted that copper is instrumental in the commodities super cycle and that the world needs more copper, making exploration key in the supply. The company observed that its Buck Lake…

WednesdayMay 08, 2024 1:24 pm

NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) Releases Q1 2024 Financial Numbers, Operation Highlights

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., are reporting on first-quarter 2024 financial results and operating highlights for its CNM-Au8 clinical program for amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). Clene Nanomedicine is a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases. Highlights of the report include the news that data from the long-term extension of Clene’s phase 2 VISIONARY-MS clinical trial of CNM-Au8® exhibits significant evidence of repair and remyelination across multiple paraclinical endpoints; the publication of an article in the “ACS Pharmacology & Translational Science,” a journal that publishes…

WednesdayMay 08, 2024 12:50 pm

NetworkNewsBreaks – Why Tartisan Nickel Corp. (CSE: TN) (OTCQB: TTSRF) Is ‘One to Watch’

Tartisan Nickel (CSE: TN) (OTCQB: TTSRF) is a Canadian mineral and battery metals exploration and mining development company. The company’s Kenbridge Nickel Project, located in the Kenora Mining District in the Province of Ontario, is an advanced-staged nickel deposit with a measured, indicated and inferred resource that has an existing 622-meter three compartment shaft. “As the world looks to utilize electric vehicles (‘EVs’) in an effort to reduce air pollution, demand for EV battery metals is on the rise,” a recent article reads. “Nickel is one of these in-demand battery metals, and there are few new, high grade development projects…

WednesdayMay 08, 2024 8:30 am

NetworkNewsBreaks – NanoViricides Inc. (NYSE American: NNVC) Lead Drug Candidate Indicates Strong Orthopoxvirus Activity

NanoViricides (NYSE American: NNVC), a global leader in broad-spectrum antiviral nanomedicines, is reporting that, in a lethal animal model, its lead drug candidate, NV-387, showed ultra-broad antiviral activity, including activity against the orthopoxvirus family, including smallpox and mpox. According to the announcement, in the model of lung infection by Ectromelia virus, oral dosing with NV-387 showed an increase in lifespan of mice comparable to oral treatment with tecovirimat (TPOXX[R], SIGA), which is currently the approved drug against smallpox. “We have completed a lethality animal study wherein animals were infected with ectromelia virus into the lungs directly,” stated the company in…

TuesdayMay 07, 2024 3:16 pm

NetworkNewsBreaks – Sekur Private Data Ltd. (CSE: SKUR) (OTCQX: SWISF) (FSE: GDT0) Inks Agreement Marking Entry into Telecom, Fintech Markets

Sekur Private Data (CSE: SKUR) (OTCQB: SWISF) (FSE: GDT0), a premier Swiss-hosted secure and private communications platform, has signed a letter of intent marking the company’s deliberate expansion into the telecom and fintech markets. According to the announcement, Sekur signed an agreement for a planned contribution of a mobile virtual network operator (“MVNO”) telecommunications company; the agreement also outlined details of a $500,000 cash infusion into Sekur Private Data by Cuentas Inc. (OTC: CUEN). Headquartered in Miami, Florida, Cuentas seamlessly integrates fintech, mobile telecommunications and real estate to serve the Hispanic demographic, particularly unbanked and underbanked communities. The contribution Cuentas…

TuesdayMay 07, 2024 2:37 pm

NetworkNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Marks Important Step in Advancing Lucid-21-302

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces the submission to ethics of a trial. Entitled “A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants,” the clinical trial application is submitted for review by a human ethics review committee (“HREC”) in Australia. The step is necessary to obtain permission to initiate the multiple ascending dose (“MAD”) trial, which follows the Phase-1 single ascending dose (“SAD”)…

TuesdayMay 07, 2024 2:13 pm

NetworkNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) and Bollinger Motors Partner with Amerit Fleet Solutions to Offer Warranty and Mobile Service

Mullen Automotive (NASDAQ: MULN), an electric vehicle (“EV”) manufacturer, and its subsidiary, Bollinger Motors, have entered into an agreement with Amerit Fleet Solutions, a leading provider of customized fleet maintenance and repair programs nationwide. The agreement calls for Amerit to provide mobile service and maintenance to Bollinger’s commercial fleet customers. According to the announcement, Bollinger and Amerit will collaborate to provide EV service and warranty support for the Bollinger B4, as well as other vehicles developed by Bollinger. Specifically, Amerit will provide maintenance, repair and warranty services to Bollinger customers located outside of the designated service area of a Bollinger…

TuesdayMay 07, 2024 2:12 pm

NetworkNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Announces Publication of Article on Emerging Candidate – Sigyn Therapy(TM)

Sigyn Therapeutics (OTCQB: SIGY), a development-stage medical technology company, today announced that it has published an article entitled: “Sigyn Therapy(TM), an Emerging Candidate to Address Endotoxemia, Sepsis and Drug-Resistant Viral & Bacterial Infections.” “When we designed Sigyn Therapy, we envisioned a medical device that could overcome the limitations of previous blood purification technologies to treat life-threatening conditions that are beyond the reach of drugs. Along with the efforts of our dedicated team, contributions from science advisors, collaborators and shareholders have helped to advance our vision toward reality,” said Jim Joyce, co-founder and CEO of Sigyn Therapeutics. “Consider that in the…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks